Skyrocketing prescription drug costs are crippling America’s healthcare system and pricing many consumers out of the medicines they need to live.  One clear answer to this healthcare crisis is to ensure consumer access to safe, effective, affordable generic drugs.

Yet today, an entire class of drugs called biopharmaceuticals lacks a clear pathway for the development and approval of generic versions.  Brand name drug manufacturers are using legal loopholes to extend their patents and the Office of Generic Drugs (OGD) lacks sufficient funding to review and approve generic drug applications.  Congress must provide a definitive FDA approval process for biogenerics, pass legislation such as the Lower PRICED Drugs Act (S. 2300) to close the loopholes that keep generic drugs off the market and increase funding for OGD to reduce its backlog and increase competition in the pharmaceutical market.

It's time to tell our lawmakers that generic drugs save lives!